logo
produits
DéTAILS DES PRODUITS
Maison > Produits >
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection

HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection

MOQ: 1000 pièces
Prix: USD
Standard Packaging: 1 pièces/boîte, 50 pièces/boîte, 100 pièces/boîte
Delivery Period: selon la quantité commandée
Méthode De Paiement: LC, T/T
Supply Capacity: 50,000pcs par mois
Les informations détaillées
Lieu d'origine
Chine
Nom de marque
FAMID
Certification
NMPA,CE
Numéro de modèle
001
Méthode d'essai:
Or colloïdal
Le temps de produire des résultats:
dans les 15 minutes
Prélèvement:
auto-collecte
Vente:
Recherchez les distributeurs/agents dans le monde entier
Description de produit
HPV E7 Oncoprotein Cervical Cancer Rapid Test Kit
Product Overview

Breakthrough new generation technology for cervical cancer screening that directly detects cancer cells and cervical cancer lesions.

Unlike traditional cervical cancer screening methods (TCT and HPV) that detect abnormal cells or HPV virus, our test assay directly identifies cancerous cells and cervical cancer lesions through E7 oncoprotein detection.

Key Features
  • 15-minute rapid test - no need to wait for lab results
  • Higher accuracy for cervical cancer screening
  • Self-sampling cervical brush technology
  • First rapid test kit worldwide to directly detect E7 oncoprotein
  • Identifies high-grade precancerous lesions before progression to cancer
E7 Oncoprotein and Cervical Cancer Progression

When E7 oncoprotein is expressed in large quantities, it causes cells to develop high-grade precancerous lesions until cancerous. Detection of E7 helps evaluate cervical precancerous lesions.

HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 0
Comparison with Current Detection Methods
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 1
Clinical Advantages
  • Pap/TCT tests result in ASC-US population with abnormal cells but cannot detect cervical cancer cells and lesions
  • DNA tests provide HPV virus infection and types but cannot detect cervical cancer cells and lesions
  • E7 oncoprotein tests detect HPV-infected cells that become cancerous and directly identify oncoprotein expression
  • Chinese FDA registered, EU registered, and CE marked
  • Patented technology in China, USA, and other countries
Clinical Applications

Direct Detection: Use E7 oncoprotein rapid kit at hospitals, clinics, or for home testing to detect cervical cancer.

Combined with TCT/Pap Smear: Use E7 to further evaluate precancerous progression when only TCT testing is available.

Combined with HPV DNA Test: Improves diagnosis specificity of cervical lesions and provides referral basis for colposcopy.

For Positive TCT/HPV DNA Patients: Identify transient infections and assess disease progression risk.

Post-Surgery Patients: Assess recurrence risk and prognosis.

For Negative TCT/HPV DNA Patients: Detect lesions to avoid missed diagnosis when DNA tests show weak or false negatives.

Sample Collection Procedure

Cervical Exfoliated Cell Sample Extraction:

  • Use sampling cervical brush placed on transformation zone of cervix
  • Turn clockwise six times
  • Insert brush into test tube containing sample release agent
Pre-Sampling Requirements
  • Avoid intravaginal medicines, douching
  • Avoid menstrual periods - no sampling three days before/after menstruation
  • Do not sample during pregnancy
Postpone sampling if experiencing abnormal vaginal bleeding, heavy bleeding, excessive secretion, or thick secretion.
Instructions for Use
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 2
produits
DéTAILS DES PRODUITS
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection
MOQ: 1000 pièces
Prix: USD
Standard Packaging: 1 pièces/boîte, 50 pièces/boîte, 100 pièces/boîte
Delivery Period: selon la quantité commandée
Méthode De Paiement: LC, T/T
Supply Capacity: 50,000pcs par mois
Les informations détaillées
Lieu d'origine
Chine
Nom de marque
FAMID
Certification
NMPA,CE
Numéro de modèle
001
Méthode d'essai:
Or colloïdal
Le temps de produire des résultats:
dans les 15 minutes
Prélèvement:
auto-collecte
Vente:
Recherchez les distributeurs/agents dans le monde entier
Quantité de commande min:
1000 pièces
Prix:
USD
Détails d'emballage:
1 pièces/boîte, 50 pièces/boîte, 100 pièces/boîte
Délai de livraison:
selon la quantité commandée
Conditions de paiement:
LC, T/T
Capacité d'approvisionnement:
50,000pcs par mois
Description de produit
HPV E7 Oncoprotein Cervical Cancer Rapid Test Kit
Product Overview

Breakthrough new generation technology for cervical cancer screening that directly detects cancer cells and cervical cancer lesions.

Unlike traditional cervical cancer screening methods (TCT and HPV) that detect abnormal cells or HPV virus, our test assay directly identifies cancerous cells and cervical cancer lesions through E7 oncoprotein detection.

Key Features
  • 15-minute rapid test - no need to wait for lab results
  • Higher accuracy for cervical cancer screening
  • Self-sampling cervical brush technology
  • First rapid test kit worldwide to directly detect E7 oncoprotein
  • Identifies high-grade precancerous lesions before progression to cancer
E7 Oncoprotein and Cervical Cancer Progression

When E7 oncoprotein is expressed in large quantities, it causes cells to develop high-grade precancerous lesions until cancerous. Detection of E7 helps evaluate cervical precancerous lesions.

HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 0
Comparison with Current Detection Methods
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 1
Clinical Advantages
  • Pap/TCT tests result in ASC-US population with abnormal cells but cannot detect cervical cancer cells and lesions
  • DNA tests provide HPV virus infection and types but cannot detect cervical cancer cells and lesions
  • E7 oncoprotein tests detect HPV-infected cells that become cancerous and directly identify oncoprotein expression
  • Chinese FDA registered, EU registered, and CE marked
  • Patented technology in China, USA, and other countries
Clinical Applications

Direct Detection: Use E7 oncoprotein rapid kit at hospitals, clinics, or for home testing to detect cervical cancer.

Combined with TCT/Pap Smear: Use E7 to further evaluate precancerous progression when only TCT testing is available.

Combined with HPV DNA Test: Improves diagnosis specificity of cervical lesions and provides referral basis for colposcopy.

For Positive TCT/HPV DNA Patients: Identify transient infections and assess disease progression risk.

Post-Surgery Patients: Assess recurrence risk and prognosis.

For Negative TCT/HPV DNA Patients: Detect lesions to avoid missed diagnosis when DNA tests show weak or false negatives.

Sample Collection Procedure

Cervical Exfoliated Cell Sample Extraction:

  • Use sampling cervical brush placed on transformation zone of cervix
  • Turn clockwise six times
  • Insert brush into test tube containing sample release agent
Pre-Sampling Requirements
  • Avoid intravaginal medicines, douching
  • Avoid menstrual periods - no sampling three days before/after menstruation
  • Do not sample during pregnancy
Postpone sampling if experiencing abnormal vaginal bleeding, heavy bleeding, excessive secretion, or thick secretion.
Instructions for Use
HPV E7 Oncoprotein Test Kit for Cervical Cancer Screening with 15 min Results, Self-Sampling, and Direct Cancer Cell Protein Detection 2
Plan du site |  Politique en matière de protection de la vie privée | Bonne qualité de la Chine Machine de qPCR de droite Fournisseur. © de Copyright 2022-2026 Guangzhou BioKey Healthy Technology Co.Ltd . Tous droits réservés.